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A recent Cochrane systematic review challenged the evidence
base for neuraminidase inhibitors (NIs) by claiming that NIs
have negligible efficacy in the treatment of influenza [1]. An
individual patient data meta-analysis seemingly contradicts
these findings [2]. The public, physicians, policy-makers and
governments are now struggling to understand how to
translate these findings to clinical practice.
Jefferson et al. [1] updated their Cochrane review of
randomized controlled trials (RCTs) that compared NIs with
placebo as treatment or prophylaxis for influenza, basing it on
study reports sent to regulators in an attempt to include full
data from all RCTs performed (60% of the data from RCTs on
oseltamivir have not been published). The review included
healthy children and adults of all ages, including people with
chronic diseases that do not affect the immune system
profoundly.
Among adults (eight trials, 3954 participants), oseltamivir
reduced the duration of symptoms by 16.8 h (95% CI 8.4–
25.1, no heterogeneity). Hospital admissions were identical in
the placebo and NI treatment arms. Pneumonia rates were
reported less frequently with treatment (numbers needed to
treat (NNT) = 100), but the reduction was mainly observed in
studies that did not collect this information systematically.
Sinusitis and otitis media had the same rates. Nausea and
vomiting were the most common adverse effects of the drug,
but the rate of withdrawal because of adverse events was
similar to that with placebo. The reduction in duration of
symptoms for adults given zanamivir as inhalation or as nasal
spray (13 studies, 5411 participants) was 14 h (95% CI 9–
28 h, low heterogeneity). A significant reduction was observed
in bronchitis rates, but not in pneumonia rates. Serious
adverse events and adverse events that led to withdrawal from
the study were not more common in the active arm than in the
placebo arm.
When given for prophylaxis among adults and children,
oseltamivir reduced the rate of symptomatic laboratory-con-
firmed influenza (relative risk (RR) 0.45 (95% CI 0.30–0.67,
NNT c. 50), but not the rates of influenza-like illnesses,
hospital admissions, or any other severe complication. Za-
namivir reduced the rates of symptomatic influenza (RR 0.39,
95% CI 0.22–0.70, NNT c. 50) and pneumonia (RR 0.30,
95% CI 0.11–0.80, NNT 311). The rates of influenza-like
illnesses were not available.
Elderly participants were separately investigated in only
four prophylaxis trials. Few elderly patients were included in
the treatment trials, and the Cochrane review did not assess
this subgroup. The original studies did not include persons
with severe underlying disorders or patients with a severe
presentation of influenza, e.g. those requiring hospital
admission.
Muthuri et al. [2]. conducted an individual patient-data
meta-analysis of observational studies, including 29 234
people from 78 centres (including our dataset [3]) hospital-
ized because of influenza A H1N1 (81.5% laboratory-con-
firmed). Patients given NIs had a lower fatality rate than
patients not treated with NIs (adjusted OR 0.81,
95% CI 0.70–0.93). Patients given treatment within 2 days
of symptom onset had a lower fatality rate than those given
later treatment (adjusted OR 0.48, 95% CI 0.41–0.56). The
meta-analysis shares two weaknesses with the observational
studies published on this issue. Patients were not random-
ized to treatment vs. no treatment or to early vs. late
treatment. Physicians had reasons for prescribing NIs in
certain patients and for not prescribing them in others. We
cannot be sure that the techniques used (adjusting for the
propensity for treatment and risk factors for mortality) can
compensate in full for this bias. Another potential source of
bias is the immortal time bias: patients given treatment and
late treatment survived at least to the day on which the
treatment was prescribed. Researchers might have published
positive results but not negative ones, and researchers
showing positive results might have been more inclined to
share their data and include them in the meta-analysis
(publication bias). We also do not know whether the results
obtained during the H1N1 pandemic can be generalized to
all influenza epidemics or pandemics.
How should these data direct practice? For healthy
people in the community, the modest reduction in symptom
duration (out of the 7-day illness duration without treat-
ment) with no other proven positive outcomes does not, in
our opinion, justify treatment with NIs. In people admitted
to hospital with severe influenza complications or severe
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deterioration in underlying disorders related to influenza,
treatment with NIs should be initiated early. National
committees will face a difficult decision on whether contin-
ual stockpiling of NIs is justified, as pandemics are rare (and
pandemics of severe disease even rarer) and cannot be
predicted [4].
An RCT addressing patients sick enough to be hospitalized
with influenza or suspected influenza is very unlikely. Given the
results of the observational studies, weak as they are, and the
relative safety of NIs, it is doubtful whether research ethics
boards would approve such a study. For a long time, these are
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